Longeveron Inc (LGVN)

$0.53 -0.01 (-1.59%)
Market Cap 11.54M
Revenue (ttm) 2.39M
Net Income (ttm) -15.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -668.20%
Debt to Equity Ratio 0.00
Volume 106,800
Avg Vol 433,868
Day's Range N/A - N/A
Shares Out 21.33M
Stochastic %K 9%
Beta 0.18
Analysts Strong Sell
Price Target $6.86

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
FullPorrtDipz
FullPorrtDipz Dec. 23 at 1:56 AM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. šŸš€ Higher relative volume on $IRBT $IOVA $SRXH $LGVN
0 Ā· Reply
Omidaz
Omidaz Dec. 22 at 8:27 PM
$LGVN any hope left for this?
1 Ā· Reply
Grant444
Grant444 Dec. 22 at 3:42 PM
$LGVN Iā€™m all out.
1 Ā· Reply
dao4570
dao4570 Dec. 20 at 3:01 PM
$LGVN ā€œOn track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled. ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacy.ā€ In 9 months if results are positive they could submit BLA based on Phase 2!!
1 Ā· Reply
Dorps332
Dorps332 Dec. 20 at 1:14 AM
$LGVN what a trash stock. With no managment supporting it
0 Ā· Reply
janlukas
janlukas Dec. 19 at 12:55 PM
$LGVN Next drug? Possible given the pipeline. Drugs from $0.96 to $100 in a few days. Plus, shorts can help.
0 Ā· Reply
volatilelt
volatilelt Dec. 19 at 10:01 AM
$LGVN Now we average down and wait for the PR that company has found a solution for non-dilutive financing? Right?
0 Ā· Reply
cfvk
cfvk Dec. 18 at 6:35 PM
$LGVN was stopped light green earlier, let's see if it wants to double bottom.
0 Ā· Reply
TuJaro
TuJaro Dec. 17 at 8:24 PM
$LGVN Volume is almost 1 million why is this not skyrocketing up, they maybe have financial difficulties, but only good news otherwise are coming out, come on investors!!!
1 Ā· Reply
Huskersnsaints
Huskersnsaints Dec. 17 at 6:33 PM
$LGVN the 7th stock to have good news recently and shockingly after a mini spike it has stayed Barely Green but hey the day is not over!!! More then likely it will close RED
0 Ā· Reply
Latest News on LGVN
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 22 days ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 23 days ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 5 weeks ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 6 weeks ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:36 PM EST - 7 weeks ago

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

LongeveronĀ® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 2 months ago

LongeveronĀ® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

LongeveronĀ® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 2 months ago

LongeveronĀ® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

LongeveronĀ® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 3 months ago

LongeveronĀ® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

LongeveronĀ® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 4 months ago

LongeveronĀ® Announces Key Leadership Updates

LongeveronĀ® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 4 months ago

LongeveronĀ® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 10:55 PM EDT - 4 months ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

LongeveronĀ® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 4 months ago

LongeveronĀ® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 4 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 4 months ago

Longeveron Announces Up To $17.5 Million Public Offering

LongeveronĀ® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 5 months ago

LongeveronĀ® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

LongeveronĀ® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 5 months ago

LongeveronĀ® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

LongeveronĀ® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 6 months ago

LongeveronĀ® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

LongeveronĀ® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 6 months ago

LongeveronĀ® Appoints Than Powell as Chief Business Officer

LongeveronĀ® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 6 months ago

LongeveronĀ® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

LongeveronĀ® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 7 months ago

LongeveronĀ® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

LongeveronĀ® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 7 months ago

LongeveronĀ® to Attend BIO International Convention 2025

LongeveronĀ® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 8 months ago

LongeveronĀ® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025, 5:31 PM EDT - 8 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

LongeveronĀ® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 8 months ago

LongeveronĀ® Announces First Quarter 2025 Financial Results and Provides Business Update

LongeveronĀ® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 8 months ago

LongeveronĀ® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

LongeveronĀ® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-Bā„¢) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 10 months ago

LongeveronĀ® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-Bā„¢) in Alzheimer's Disease

LongeveronĀ® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 10 months ago

LongeveronĀ® to Present at the 37th Annual Roth Conference

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:04 PM EST - 10 months ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

LongeveronĀ® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 10 months ago

LongeveronĀ® Announces Full-Year 2024 Financial Results and Provides Business Update

LongeveronĀ® Announces World Health Organization Approval of ā€œlaromestrocelā€ as International Non-proprietary Name for Stem Cell Therapy Lomecel-Bā„¢

Feb 18, 2025, 9:25 AM EST - 11 months ago

LongeveronĀ® Announces World Health Organization Approval of ā€œlaromestrocelā€ as International Non-proprietary Name for Stem Cell Therapy Lomecel-Bā„¢

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:37 PM EST - 1 year ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

LongeveronĀ® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

LongeveronĀ® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

LongeveronĀ® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

LongeveronĀ® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

LongeveronĀ® Presents Lomecel-Bā„¢Ā Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

LongeveronĀ® Presents Lomecel-Bā„¢Ā Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

LongeveronĀ® Presents Lomecel-Bā„¢ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

LongeveronĀ® Presents Lomecel-Bā„¢ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

LongeveronĀ® Lomecel-Bā„¢Ā Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

LongeveronĀ® Lomecel-Bā„¢Ā Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

LongeveronĀ® Lomecel-Bā„¢Ā 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

LongeveronĀ® Lomecel-Bā„¢Ā 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

LongeveronĀ® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

LongeveronĀ® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

LongeveronĀ® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

LongeveronĀ® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:58 PM EDT - 1 year ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

LongeveronĀ® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-Bā„¢ in Mild Alzheimer's Disease at the Alzheimer's Association International ConferenceĀ® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

LongeveronĀ® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-Bā„¢ in Mild Alzheimer's Disease at the Alzheimer's Association International ConferenceĀ® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

LongeveronĀ® Announces U.S. FDA Grants Lomecel-Bā„¢Ā Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 10, 2024, 7:30 AM EDT - 1 year ago

LongeveronĀ® Announces U.S. FDA Grants Lomecel-Bā„¢Ā Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Neha Motwani Elected to LongeveronĀ® Board of Directors

Jul 9, 2024, 9:00 AM EDT - 1 year ago

Neha Motwani Elected to LongeveronĀ® Board of Directors

FullPorrtDipz
FullPorrtDipz Dec. 23 at 1:56 AM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. šŸš€ Higher relative volume on $IRBT $IOVA $SRXH $LGVN
0 Ā· Reply
Omidaz
Omidaz Dec. 22 at 8:27 PM
$LGVN any hope left for this?
1 Ā· Reply
Grant444
Grant444 Dec. 22 at 3:42 PM
$LGVN Iā€™m all out.
1 Ā· Reply
dao4570
dao4570 Dec. 20 at 3:01 PM
$LGVN ā€œOn track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication and is fully enrolled. ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacy.ā€ In 9 months if results are positive they could submit BLA based on Phase 2!!
1 Ā· Reply
Dorps332
Dorps332 Dec. 20 at 1:14 AM
$LGVN what a trash stock. With no managment supporting it
0 Ā· Reply
janlukas
janlukas Dec. 19 at 12:55 PM
$LGVN Next drug? Possible given the pipeline. Drugs from $0.96 to $100 in a few days. Plus, shorts can help.
0 Ā· Reply
volatilelt
volatilelt Dec. 19 at 10:01 AM
$LGVN Now we average down and wait for the PR that company has found a solution for non-dilutive financing? Right?
0 Ā· Reply
cfvk
cfvk Dec. 18 at 6:35 PM
$LGVN was stopped light green earlier, let's see if it wants to double bottom.
0 Ā· Reply
TuJaro
TuJaro Dec. 17 at 8:24 PM
$LGVN Volume is almost 1 million why is this not skyrocketing up, they maybe have financial difficulties, but only good news otherwise are coming out, come on investors!!!
1 Ā· Reply
Huskersnsaints
Huskersnsaints Dec. 17 at 6:33 PM
$LGVN the 7th stock to have good news recently and shockingly after a mini spike it has stayed Barely Green but hey the day is not over!!! More then likely it will close RED
0 Ā· Reply
JohnTrack
JohnTrack Dec. 17 at 3:41 PM
$LGVN monitoring pullbacks
0 Ā· Reply
poilu
poilu Dec. 17 at 3:09 PM
$LGVN Patents are fine....but revenue comes from sales.
1 Ā· Reply
27words
27words Dec. 17 at 3:00 PM
$LGVN patent for female sexual dysfunction sounds like a winner to me
0 Ā· Reply
DARKP00L
DARKP00L Dec. 17 at 2:45 PM
$LGVN 09:17 on Dec. 17 2025 Longeveron Secures USPTO Patent For MSC Therapy Targeting Female Sexual Dysfunction #tradeideas
0 Ā· Reply
janlukas
janlukas Dec. 17 at 2:34 PM
$LGVN Nothing is going to happen here because it's manipulated but honestly it's news that would normally push a stock to $100 or nothing less.
1 Ā· Reply
kebrik
kebrik Dec. 17 at 2:30 PM
Today's movers: $VYNE, $BEAT, $SRXH, $YCBD, and $LGVN
0 Ā· Reply
27words
27words Dec. 17 at 2:27 PM
$LGVN lets go
1 Ā· Reply
dbr_island
dbr_island Dec. 17 at 2:25 PM
VYNE never ignore my table pounds šŸšØMIGIšŸšØ now Iā€™m pounding the table here šŸšØ $UDMY $BEAT $YCBD $LGVN $VTGN watching closely
0 Ā· Reply
Dorps332
Dorps332 Dec. 17 at 2:22 PM
$LGVN great another patent that we donā€™t have funds to support. Having all these patents are greats exxcept when the company has zero cash to pursue them
0 Ā· Reply
dbr_island
dbr_island Dec. 17 at 2:20 PM
$VYNE never ignore my table pounds $MIGI now Iā€™m pounding the table here šŸšØšŸšØšŸšØ $LGVN $ISPO $ATPC what a morning
1 Ā· Reply
volatilelt
volatilelt Dec. 17 at 2:18 PM
$LGVN Alive ? Let's roll
0 Ā· Reply
JohnTrack
JohnTrack Dec. 17 at 2:18 PM
$LGVN Stem cell patent win! https://www.rapidticker.com/news/lgvn-longeveron-granted-us-patent-for-7a746f
0 Ā· Reply